Effectiveness and safety of Chaihu-Shugan-San for treating depression based on clinical cases: An updated systematic review and meta-analysis

Chaihu-Shugan-San (CSS), a Traditional Chinese Medicine formula, has been widely used for treating depression since the Ming Dynasty, as recorded in Jingyue Quanshu, but its effectiveness and safety lack comprehensive and objective evaluation. Based on our meta-analysis, we aimed to adequately evalu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Medicine (Baltimore) 2024-06, Vol.103 (26), p.e38668
Hauptverfasser: Zhang, Xiaohang, Zhao, Qiulong, Wang, Yang, Mao, Yaqing, Sun, Yue, Bian, Xiaokun
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 26
container_start_page e38668
container_title Medicine (Baltimore)
container_volume 103
creator Zhang, Xiaohang
Zhao, Qiulong
Wang, Yang
Mao, Yaqing
Sun, Yue
Bian, Xiaokun
description Chaihu-Shugan-San (CSS), a Traditional Chinese Medicine formula, has been widely used for treating depression since the Ming Dynasty, as recorded in Jingyue Quanshu, but its effectiveness and safety lack comprehensive and objective evaluation. Based on our meta-analysis, we aimed to adequately evaluate the efficacy and risk of CSS by considering the latest clinical literature. Multiple databases, including PubMed, Embase, Web of Science, SinoMed, China National Knowledge Infrastructure, Chongqing VIP, and Wanfang, were used to collect clinical data. The quality of the included clinical studies was assessed using the Cochrane Risk of Bias Tool, and the data were meta-analyzed using Review Manager 5.0 and Stata 17. The data were obtained from a genome-wide association study, and Mendelian randomization (MR) was performed using R Software 4.3.2 with the TwoSampleMR and MR Pleiotropy RESidual Sum and Outlier packages. A total of 15 studies with 1034 patients and 6 antidepressant drugs were included in this work. Meta-analyses revealed that drug combinations of CSS and antidepressants significantly improved depressive symptoms (weighted mean difference = -4.21; 95% confidence interval [CI]: -5.62--2.81), increased the effective rate (odds ratio [OR] = 3.82; 95% CI: 2.44-6.83), and reduced side effects (OR = -3.55; 95% CI: -5.66--1.43) compared with antidepressant monotherapy. Additionally, compared with antidepressant monotherapy, CSS alone exhibited fewer side effects (95% CI:-9.25--6.95). Like antidepressants, CSS also improved depressive symptoms (weighted mean difference = -0.05; 95% CI: -0.63--0.52) and increased the effective rate (OR = 1.07; 95% CI: 0.52-2.20). Additionally, MR was used to evaluate the safety of traditional antidepressants, as there was a causal association between amitriptyline and body mass index. This analysis demonstrated that compared with traditional antidepressants, CSS combined with antidepressants was more effective and safer for treating depressed patients. MR showed that a causal relationship may exist between amitriptyline and body mass index. Therefore, clinicians should carefully consider the advantages and potential drawbacks of Traditional Chinese Medicine and classic drugs to serve patients better.
doi_str_mv 10.1097/MD.0000000000038668
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11466128</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3073654359</sourcerecordid><originalsourceid>FETCH-LOGICAL-c286t-b19341127e5911d67aa32bc149e81501faa60278b08493ee2324785746ced1ca3</originalsourceid><addsrcrecordid>eNpdUctuFDEQtBCILIEvQEI-cpng19hjLijahIeUKIfA2erx9OwazXgW27NoP4J_ZvIgQPrSra6uqpaKkNecnXBmzbvLsxP2t2SjdfOErHgtdVVbrZ6SFWOirow16oi8yPk7Y1waoZ6TI9lYxRWzK_LrvO_Rl7DHiDlTiB3N0GM50Kmn6y2E7Vxdb-cNxOoaIu2nREtCKCFuaIe7tJDCFGkLGTu6DH4IMXgYqF82-T09jXTedVAWNB9ywXGheppwH_DnrduIBSqIMBxyyC_Jsx6GjK_u-zH59vH86_pzdXH16cv69KLyotGlarmVinNhsLacd9oASNF6riw2vGa8B9BMmKZljbISUUihTFMbpT123IM8Jh_udHdzO2LnMZYEg9ulMEI6uAmC-x-JYes2095xrrTmolkU3t4rpOnHjLm4MWSPwwARpzk7yYzUtZK1XU7l3alPU84J-wcfztxNku7yzD1OcmG9-ffFB86f6ORvxeSbnQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3073654359</pqid></control><display><type>article</type><title>Effectiveness and safety of Chaihu-Shugan-San for treating depression based on clinical cases: An updated systematic review and meta-analysis</title><source>Open Access: PubMed Central</source><source>Wolters Kluwer Open Health</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>IngentaConnect Open Access Journals</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Zhang, Xiaohang ; Zhao, Qiulong ; Wang, Yang ; Mao, Yaqing ; Sun, Yue ; Bian, Xiaokun</creator><creatorcontrib>Zhang, Xiaohang ; Zhao, Qiulong ; Wang, Yang ; Mao, Yaqing ; Sun, Yue ; Bian, Xiaokun</creatorcontrib><description>Chaihu-Shugan-San (CSS), a Traditional Chinese Medicine formula, has been widely used for treating depression since the Ming Dynasty, as recorded in Jingyue Quanshu, but its effectiveness and safety lack comprehensive and objective evaluation. Based on our meta-analysis, we aimed to adequately evaluate the efficacy and risk of CSS by considering the latest clinical literature. Multiple databases, including PubMed, Embase, Web of Science, SinoMed, China National Knowledge Infrastructure, Chongqing VIP, and Wanfang, were used to collect clinical data. The quality of the included clinical studies was assessed using the Cochrane Risk of Bias Tool, and the data were meta-analyzed using Review Manager 5.0 and Stata 17. The data were obtained from a genome-wide association study, and Mendelian randomization (MR) was performed using R Software 4.3.2 with the TwoSampleMR and MR Pleiotropy RESidual Sum and Outlier packages. A total of 15 studies with 1034 patients and 6 antidepressant drugs were included in this work. Meta-analyses revealed that drug combinations of CSS and antidepressants significantly improved depressive symptoms (weighted mean difference = -4.21; 95% confidence interval [CI]: -5.62--2.81), increased the effective rate (odds ratio [OR] = 3.82; 95% CI: 2.44-6.83), and reduced side effects (OR = -3.55; 95% CI: -5.66--1.43) compared with antidepressant monotherapy. Additionally, compared with antidepressant monotherapy, CSS alone exhibited fewer side effects (95% CI:-9.25--6.95). Like antidepressants, CSS also improved depressive symptoms (weighted mean difference = -0.05; 95% CI: -0.63--0.52) and increased the effective rate (OR = 1.07; 95% CI: 0.52-2.20). Additionally, MR was used to evaluate the safety of traditional antidepressants, as there was a causal association between amitriptyline and body mass index. This analysis demonstrated that compared with traditional antidepressants, CSS combined with antidepressants was more effective and safer for treating depressed patients. MR showed that a causal relationship may exist between amitriptyline and body mass index. Therefore, clinicians should carefully consider the advantages and potential drawbacks of Traditional Chinese Medicine and classic drugs to serve patients better.</description><identifier>ISSN: 0025-7974</identifier><identifier>ISSN: 1536-5964</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000038668</identifier><identifier>PMID: 38941409</identifier><language>eng</language><publisher>United States: Lippincott Williams &amp; Wilkins</publisher><subject>Antidepressive Agents - adverse effects ; Antidepressive Agents - therapeutic use ; Depression - drug therapy ; Drugs, Chinese Herbal - adverse effects ; Drugs, Chinese Herbal - therapeutic use ; Humans ; Plant Extracts - adverse effects ; Plant Extracts - therapeutic use ; Systematic Review and Meta-Analysis ; Treatment Outcome</subject><ispartof>Medicine (Baltimore), 2024-06, Vol.103 (26), p.e38668</ispartof><rights>Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.</rights><rights>Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc. 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c286t-b19341127e5911d67aa32bc149e81501faa60278b08493ee2324785746ced1ca3</cites><orcidid>0009-0000-5635-1625</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11466128/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11466128/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38941409$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Xiaohang</creatorcontrib><creatorcontrib>Zhao, Qiulong</creatorcontrib><creatorcontrib>Wang, Yang</creatorcontrib><creatorcontrib>Mao, Yaqing</creatorcontrib><creatorcontrib>Sun, Yue</creatorcontrib><creatorcontrib>Bian, Xiaokun</creatorcontrib><title>Effectiveness and safety of Chaihu-Shugan-San for treating depression based on clinical cases: An updated systematic review and meta-analysis</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description>Chaihu-Shugan-San (CSS), a Traditional Chinese Medicine formula, has been widely used for treating depression since the Ming Dynasty, as recorded in Jingyue Quanshu, but its effectiveness and safety lack comprehensive and objective evaluation. Based on our meta-analysis, we aimed to adequately evaluate the efficacy and risk of CSS by considering the latest clinical literature. Multiple databases, including PubMed, Embase, Web of Science, SinoMed, China National Knowledge Infrastructure, Chongqing VIP, and Wanfang, were used to collect clinical data. The quality of the included clinical studies was assessed using the Cochrane Risk of Bias Tool, and the data were meta-analyzed using Review Manager 5.0 and Stata 17. The data were obtained from a genome-wide association study, and Mendelian randomization (MR) was performed using R Software 4.3.2 with the TwoSampleMR and MR Pleiotropy RESidual Sum and Outlier packages. A total of 15 studies with 1034 patients and 6 antidepressant drugs were included in this work. Meta-analyses revealed that drug combinations of CSS and antidepressants significantly improved depressive symptoms (weighted mean difference = -4.21; 95% confidence interval [CI]: -5.62--2.81), increased the effective rate (odds ratio [OR] = 3.82; 95% CI: 2.44-6.83), and reduced side effects (OR = -3.55; 95% CI: -5.66--1.43) compared with antidepressant monotherapy. Additionally, compared with antidepressant monotherapy, CSS alone exhibited fewer side effects (95% CI:-9.25--6.95). Like antidepressants, CSS also improved depressive symptoms (weighted mean difference = -0.05; 95% CI: -0.63--0.52) and increased the effective rate (OR = 1.07; 95% CI: 0.52-2.20). Additionally, MR was used to evaluate the safety of traditional antidepressants, as there was a causal association between amitriptyline and body mass index. This analysis demonstrated that compared with traditional antidepressants, CSS combined with antidepressants was more effective and safer for treating depressed patients. MR showed that a causal relationship may exist between amitriptyline and body mass index. Therefore, clinicians should carefully consider the advantages and potential drawbacks of Traditional Chinese Medicine and classic drugs to serve patients better.</description><subject>Antidepressive Agents - adverse effects</subject><subject>Antidepressive Agents - therapeutic use</subject><subject>Depression - drug therapy</subject><subject>Drugs, Chinese Herbal - adverse effects</subject><subject>Drugs, Chinese Herbal - therapeutic use</subject><subject>Humans</subject><subject>Plant Extracts - adverse effects</subject><subject>Plant Extracts - therapeutic use</subject><subject>Systematic Review and Meta-Analysis</subject><subject>Treatment Outcome</subject><issn>0025-7974</issn><issn>1536-5964</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdUctuFDEQtBCILIEvQEI-cpng19hjLijahIeUKIfA2erx9OwazXgW27NoP4J_ZvIgQPrSra6uqpaKkNecnXBmzbvLsxP2t2SjdfOErHgtdVVbrZ6SFWOirow16oi8yPk7Y1waoZ6TI9lYxRWzK_LrvO_Rl7DHiDlTiB3N0GM50Kmn6y2E7Vxdb-cNxOoaIu2nREtCKCFuaIe7tJDCFGkLGTu6DH4IMXgYqF82-T09jXTedVAWNB9ywXGheppwH_DnrduIBSqIMBxyyC_Jsx6GjK_u-zH59vH86_pzdXH16cv69KLyotGlarmVinNhsLacd9oASNF6riw2vGa8B9BMmKZljbISUUihTFMbpT123IM8Jh_udHdzO2LnMZYEg9ulMEI6uAmC-x-JYes2095xrrTmolkU3t4rpOnHjLm4MWSPwwARpzk7yYzUtZK1XU7l3alPU84J-wcfztxNku7yzD1OcmG9-ffFB86f6ORvxeSbnQ</recordid><startdate>20240628</startdate><enddate>20240628</enddate><creator>Zhang, Xiaohang</creator><creator>Zhao, Qiulong</creator><creator>Wang, Yang</creator><creator>Mao, Yaqing</creator><creator>Sun, Yue</creator><creator>Bian, Xiaokun</creator><general>Lippincott Williams &amp; Wilkins</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0009-0000-5635-1625</orcidid></search><sort><creationdate>20240628</creationdate><title>Effectiveness and safety of Chaihu-Shugan-San for treating depression based on clinical cases: An updated systematic review and meta-analysis</title><author>Zhang, Xiaohang ; Zhao, Qiulong ; Wang, Yang ; Mao, Yaqing ; Sun, Yue ; Bian, Xiaokun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c286t-b19341127e5911d67aa32bc149e81501faa60278b08493ee2324785746ced1ca3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antidepressive Agents - adverse effects</topic><topic>Antidepressive Agents - therapeutic use</topic><topic>Depression - drug therapy</topic><topic>Drugs, Chinese Herbal - adverse effects</topic><topic>Drugs, Chinese Herbal - therapeutic use</topic><topic>Humans</topic><topic>Plant Extracts - adverse effects</topic><topic>Plant Extracts - therapeutic use</topic><topic>Systematic Review and Meta-Analysis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Xiaohang</creatorcontrib><creatorcontrib>Zhao, Qiulong</creatorcontrib><creatorcontrib>Wang, Yang</creatorcontrib><creatorcontrib>Mao, Yaqing</creatorcontrib><creatorcontrib>Sun, Yue</creatorcontrib><creatorcontrib>Bian, Xiaokun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Xiaohang</au><au>Zhao, Qiulong</au><au>Wang, Yang</au><au>Mao, Yaqing</au><au>Sun, Yue</au><au>Bian, Xiaokun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness and safety of Chaihu-Shugan-San for treating depression based on clinical cases: An updated systematic review and meta-analysis</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2024-06-28</date><risdate>2024</risdate><volume>103</volume><issue>26</issue><spage>e38668</spage><pages>e38668-</pages><issn>0025-7974</issn><issn>1536-5964</issn><eissn>1536-5964</eissn><abstract>Chaihu-Shugan-San (CSS), a Traditional Chinese Medicine formula, has been widely used for treating depression since the Ming Dynasty, as recorded in Jingyue Quanshu, but its effectiveness and safety lack comprehensive and objective evaluation. Based on our meta-analysis, we aimed to adequately evaluate the efficacy and risk of CSS by considering the latest clinical literature. Multiple databases, including PubMed, Embase, Web of Science, SinoMed, China National Knowledge Infrastructure, Chongqing VIP, and Wanfang, were used to collect clinical data. The quality of the included clinical studies was assessed using the Cochrane Risk of Bias Tool, and the data were meta-analyzed using Review Manager 5.0 and Stata 17. The data were obtained from a genome-wide association study, and Mendelian randomization (MR) was performed using R Software 4.3.2 with the TwoSampleMR and MR Pleiotropy RESidual Sum and Outlier packages. A total of 15 studies with 1034 patients and 6 antidepressant drugs were included in this work. Meta-analyses revealed that drug combinations of CSS and antidepressants significantly improved depressive symptoms (weighted mean difference = -4.21; 95% confidence interval [CI]: -5.62--2.81), increased the effective rate (odds ratio [OR] = 3.82; 95% CI: 2.44-6.83), and reduced side effects (OR = -3.55; 95% CI: -5.66--1.43) compared with antidepressant monotherapy. Additionally, compared with antidepressant monotherapy, CSS alone exhibited fewer side effects (95% CI:-9.25--6.95). Like antidepressants, CSS also improved depressive symptoms (weighted mean difference = -0.05; 95% CI: -0.63--0.52) and increased the effective rate (OR = 1.07; 95% CI: 0.52-2.20). Additionally, MR was used to evaluate the safety of traditional antidepressants, as there was a causal association between amitriptyline and body mass index. This analysis demonstrated that compared with traditional antidepressants, CSS combined with antidepressants was more effective and safer for treating depressed patients. MR showed that a causal relationship may exist between amitriptyline and body mass index. Therefore, clinicians should carefully consider the advantages and potential drawbacks of Traditional Chinese Medicine and classic drugs to serve patients better.</abstract><cop>United States</cop><pub>Lippincott Williams &amp; Wilkins</pub><pmid>38941409</pmid><doi>10.1097/MD.0000000000038668</doi><orcidid>https://orcid.org/0009-0000-5635-1625</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0025-7974
ispartof Medicine (Baltimore), 2024-06, Vol.103 (26), p.e38668
issn 0025-7974
1536-5964
1536-5964
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11466128
source Open Access: PubMed Central; Wolters Kluwer Open Health; MEDLINE; DOAJ Directory of Open Access Journals; IngentaConnect Open Access Journals; Alma/SFX Local Collection; EZB Electronic Journals Library
subjects Antidepressive Agents - adverse effects
Antidepressive Agents - therapeutic use
Depression - drug therapy
Drugs, Chinese Herbal - adverse effects
Drugs, Chinese Herbal - therapeutic use
Humans
Plant Extracts - adverse effects
Plant Extracts - therapeutic use
Systematic Review and Meta-Analysis
Treatment Outcome
title Effectiveness and safety of Chaihu-Shugan-San for treating depression based on clinical cases: An updated systematic review and meta-analysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T10%3A42%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20and%20safety%20of%20Chaihu-Shugan-San%20for%20treating%20depression%20based%20on%20clinical%20cases:%20An%20updated%20systematic%20review%20and%20meta-analysis&rft.jtitle=Medicine%20(Baltimore)&rft.au=Zhang,%20Xiaohang&rft.date=2024-06-28&rft.volume=103&rft.issue=26&rft.spage=e38668&rft.pages=e38668-&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000038668&rft_dat=%3Cproquest_pubme%3E3073654359%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3073654359&rft_id=info:pmid/38941409&rfr_iscdi=true